Introduction
Pneumocystis carinii is an important pulmonary pathogen responsible for morbidity and mortality in patients with AIDS. Cases of pneumocystosis have also been reported in patients receiving immunosuppressive therapy associated with organ transplantation (in those not receiving specific chemoprophylaxis) and in malignant blood diseases. [1] [2] [3] The efficacies of several new compounds are being extensively evaluated in vitro and in animal models. Agents in current clinical use have limitations; there is a need for more potent and less toxic compounds or new drug combinations. [4] [5] [6] [7] Lactoferrin is an iron-binding glycoprotein that is synthesized by cells of the mucosal epithelium and neutrophils and released in response to inflammatory stimuli. [8] [9] [10] Near the amino terminus of lactoferrin, there is a strongly basic region that binds to a variety of anionic biological molecules, including lipid A and glycosaminoglycans, which are found on the surface of most cells and in most extracellular matrices. 11, 12 Several authors have reported that lactoferrins have antimicrobial activity in vitro, and lactoferrin treatment in vivo has been reported to reduce the incidence of Gram-negative bacteraemia. 10, [13] [14] [15] [16] Recent studies have demonstrated that lactoferrin also has activity against candida. [17] [18] [19] This activity is commonly attributed to its ability to bind and sequester environmental iron. 20 The iron-free form of lactoferrin (apo-lactoferrin) is able to kill both Candida albicans and Candida krusei, by mechanisms related to alterations in cell surface permeability. 21 It has been demonstrated recently that non-transferrinbound iron is increased in the lower respiratory tracts of patients with P. carinii pneumonia and that iron chelators are effective as anti-P. carinii agents in experimental models. [22] [23] [24] [25] There is also evidence that combinations of macrolides and sulphamethoxazole, clindamycin and primaquine, atovaquone and dihydrofolate reductase inhibitors, and trimethoprim-sulphamethoxazole (TMP-SMX) have increased activity against P. carinii in vitro in the rat model and in humans. [26] [27] [28] In the present study we investigated the in vitro activity of lactoferrins alone and in combination with other clinically used antimicrobial agents against P. carinii and compared their activity with that of TMP-SMX.
Materials and methods

Parasite preparation and cell culture
Three clinical isolates of P. carinii were obtained from bronchoalveolar lavages of three immunocompromised patients who had not received prior anti-P. carinii therapy. 29 Briefly, the organisms were resuspended in 0.1 mL of PBS. After addition of 0.1 mL of FDA 40 mg/L and 0.03 mL of propidium iodide 20 mg/L and incubation at room temperature for 5 min, the incubation mixtures were further diluted with an equal volume of PBS and analysed by flow cytometry.
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Inhibition of growth of
The human lung epithelial cell line A-549 (BioWhittaker) was maintained in 25 cm 2 tissue culture flasks. Medium consisted of DMEM (BioWhittaker) containing 0.10 mg/L Fe(NO 3 ) 3 with 10% fetal calf serum (BioWhittaker), 1% L-glutamine (BioWhittaker), 20 mM N-2-hydroxyethylpiperazine-N-ethanesulphonic acid (HEPES) (SigmaAldrich), penicillin G 100 U/mL, streptomycin 100 mg/L and amphotericin B 0.5 mg/L. Cells were detatched from the surface of flasks using 0.25% trypsin and 0.53 mM EDTA in PBS; then they were counted using a haemocytometer. Forty-eight hours before P. carinii inoculation, 5 ϫ 10 3 A549 viable cells/well were inoculated into 96-well plates in a total volume of 0.2 mL. Viability was assessed by trypan blue exclusion. After 48 h, monolayers were washed with DMEM to remove nonadherent epithelial cells and infection was initiated by adding 0.2 mL of P. carinii inoculum (c.1 ϫ 10 3 organisms) in new growth medium to an adherent layer of 50-70% confluent cells. Infected cell cultures were kept at 37°C in 5% CO 2 throughout the study.
Drugs
Compounds were all purchased from Sigma-Aldrich, except clarithromycin (Abbott, Rome, Italy). Iron-free human lactoferrin (lactoferrin H) and iron-free bovine lactoferrin (lactoferrin B) were dissolved in DMEM. Trimethoprim, pyrimethamine and clarithromycin were dissolved in methanol/acetone (1:1) at a concentration of 1 mg/mL. Sulphamethoxazole was dissolved in dimethylsulphoxide at 1 mg/mL. Minocycline was dissolved in distilled water at 1 mg/mL. Solutions of drugs were made fresh on the day of assay or stored at -80°C in the dark for short periods.
Susceptibility testing
Serial dilutions of each drug were prepared in DMEM. All drugs were tested at concentrations close to that which could be achieved clinically. Lactoferrins H and B were tested at concentrations of 1, 10 and 20 mg/L, clarithromycin and minocycline at 1, 2 and 4 mg/L and pyrimethamine at 0.1, 0.2 and 0.4 mg/L. TMP-SMX used as reference drug combination was tested at concentrations of 0.8/4, 1.6/8 and 3.2/16 mg/L. Preliminary experiments indicated that the final concentrations of methanol, acetone and dimethylsulphoxide (р0.1%) used in the dilution of drugs did not inhibit the growth of P. carinii. In experiments to test drug interactions, the final concentrations in the culture medium were 1, 10 and 20 mg/L for the lactoferrins, 1, 2 and 4 mg/L for clarithromycin and minocycline, and 0.1, 0.2 and 0.4 mg/L for pyrimethamine. Antibioticfree plates were used as controls in the study. Experiments were performed in triplicate. P. carinii was added at a concentration of 10 2 -10 3 organisms per well. The monolayers were incubated at 37°C in 5% CO 2 . After 72 h, 0.2 mL of supernatant containing nonadherent organisms was removed from each triplicate well and centrifuged (1800g for 15 min); P. carinii vegetative and cystic forms (precystic forms and mature cysts) were quantified by counting P. carinii nuclei in duplicate Giemsa-stained 10 L drops delivered on to 25 mm 2 squares on microscope slides. The A549 cells together with adherent P. carinii were removed from the plates by trituration following incubation in 1 mL of Ca 2ϩ -and Mg 2ϩ -free Hanks' balanced salt solution containing 10 mM EDTA for 30 min at 37°C. 6 The suspensions were centrifuged (1800g for 15 min) and detached organisms were quantified by Giemsa staining, as described above.
The cytotoxicity of the lactoferrins was determined by the CellTiter 96 AQ cell proliferation assay (Promega Corp., Lyon, France). Control for each cytotoxicity assay included (i) uninfected cells incubated in DMEM; (ii) infected cells incubated in DMEM; and (iii) cells exposed to a freezethawed lysate containing 5 ϫ 10 3 P. carinii equivalents in DMEM.
Analysis of results
The activity of each agent and combination was evaluated by counting viable parasites from plates with antimicrobialsupplemented medium and comparing it with the count from control plates without drugs (counts were total numbers of parasites in the cell layer and supernatant). The average number of P. carinii parasites per millilitre was calculated by counting 50 oil-immersion fields (ϫ1000 magnification) of each of three slides.
The 50% and 90% inhibitory concentrations (IC 50 and IC 90 , respectively) of the drug were defined as the concentrations required to produce 50% and 90% reduction, respectively, in the mean cyst or trophozoite counts com-pared with controls without drug after 72 h incubation in the presence of drugs.
The activity of each compound was also expressed by calculating the ratio of the cystic and trophic form numbers in cultures containing lactoferrin H or B at 20 mg/L, singly or in combination with other agents, to the number of cysts and trophozoites in control cultures after 72 h incubation.
Cytotoxicity was calculated from the following formula: ((mean optical density (OD) of uninfected cells -mean OD of infected cells)/mean OD of uninfected cells) ϫ 100. Values of 0-5%, 6-25%, 26-50% and 51-100% were considered to indicate no toxicity, mild toxicity, moderate toxicity and severe toxicity, respectively, for A549 cells.
Results
In control plates without drugs, the number of P. carinii nuclei increased by at least three-fold over 3 days. In the absence of antibiotic, the mean number of parasites after 3 days was 49.5 (range 16-65) when calculated by counting 50 oil-immersion fields.
Lactoferrins H and B had similar effects (Table I) . Lactoferrin B tested alone was more effective than lactoferrin H, with a higher activity against trophozoites than cysts. Lactoferrin B suppressed the growth of cysts and trophozoites by Ͼ60% at 20 mg/L (IC 50 20 mg/L). Lactoferrin H, at the same concentration, showed slightly less activity against cysts and trophozoites, producing Ͼ50% reduction in the mean cyst and nucleus counts (IC 50 20 mg/L). Neither lactoferrin B nor lactoferrin H achieved a 90% inhibitory effect at the concentrations tested, so their IC 90 is Ͼ20 mg/L.
The results with combinations of agents are shown in Tables II and III . The agents used in combination were superior to single-agent activity in reducing the cyst and trophozoite counts. The activity of lactoferrins was improved when these compounds were combined with all other compounds at the highest concentrations tested. Lactoferrin B 20 mg/L combined with clarithromycin 4 mg/L showed the highest anti-P. carinii activity, with a decrease In contrast, lactoferrins in combination with pyrimethamine and minocycline did not reduce trophozoite and cyst numbers by Ͼ90%, except the combination of lactoferrin B with pyrimethamine or minocycline against trophozoites. The only combination that achieved a 90% inhibitory effect for trophozoites or cysts was the combination of clarithromycin with either of the two lactoferrins. TMP-SMX suppressed the growth of cysts and trophozoites by Ͼ60% at 0.8/4 mg/L and 1.6/8 mg/L and by Ͼ90% at 3.2/16 mg/L and 1.6/8 mg/L (Table I) .
Ratios of the peak number of viable organisms in drugtreated cultures to the peak number in control cultures showed that lactoferrin B 20 mg/L showed the highest activity against both cysts and trophozoites (peak ratio 0.39 and 0.37, respectively). Lactoferrin H tested alone at 20 mg/L showed similar activity (cyst ratio, 0.42; trophozoite ratio, 0.41). Lactoferrin B 20 mg/L in combination with clarithromycin 4 mg/L had in vitro anti-P. carinii activity (cyst ratio, 0.06; trophozoite ratio, 0.02) comparable to that of TMP-SMX (cyst ratio, 0.06; trophozoite ratio, 0.08). These results are summarized in Table I .
The cytotoxicity of lactoferrins alone (-7.3% to 12.2% cytotoxicity) and in all combinations (-5.8% to 8.3% cytotoxicity) was very low.
Discussion
P. carinii is a common pathogen that frequently causes pulmonary infection in immunocompromised individuals. In this study, we focused our attention on lactoferrin, since it has been demonstrated that this milk protein not only can inhibit the growth of several bacteria and Candida spp. but also has important activity against several viruses, such as HIV and herpes simplex virus. 17, 30 Lactoferrins are ironbinding proteins found in mucosal secretions and in the specific granules of polymorphonuclear leucocytes. A variety of functions have been ascribed to this protein although its physiological role remains to be defined fully. It appears to contribute to antimicrobial host defence. It has direct effects on pathogenic microorganisms, including bacteriostasis and the induction of microbial iron uptake systems. It has been suggested that the antimicrobial activity of lactoferrin arises from its sequestration of environmental iron, which would cause nutritional deprivation in susceptible organisms. However, a number of other potential mechanisms by which lactoferrin inhibits the growth of several microorganisms have been suggested, including structural changes in the microbial cell wall, complete loss of membrane potential and integrity, indirect effects on enzyme activation, an increased generation of metabolic by-products of aerobic metabolism, iron deprivation and combinations of these factors. 8, 10, [12] [13] [14] [15] [16] [17] The antimicrobial activities of lactoferrins make it a promising compound for combination therapy. The drugs tested in combination with lactoferrin in this study have distinct modes of action. Pyrimethamine is a specific inhibitor of dihydrofolate reductase in many microorganisms; this enzyme is involved in folate synthesis. Pyrimethamine has only a static effect on parasite growth. The antimicrobial activity of macrolides and tetracyclines results from their ability to inhibit protein synthesis by binding to the In our experiments, lactoferrin had good activity against P. carinii, and this activity was enhanced when lactoferrin was combined with other drugs. The most active combination tested was lactoferrin plus clarithromycin. This result is in line with other studies that reported anti-P. carinii activity when lactoferrins were combined with clarithromycin, pyrimethamine or minocycline. 17, 32 This interaction mechanism appears to be complex. As mentioned above, lactoferrin has multiple mechanisms of antimicrobial action, while clarithromycin and minocycline inhibit protein synthesis and pyrimethamine indirectly inhibits folate synthesis. The additive effect of these compounds may result from the cumulative inhibitory effect on different, essential metabolic pathways.
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The cytotoxicity assay indicates that these combinations are safe. Our results showed that the combinations tested were active in inhibiting P. carinii at concentrations which appeared to be non-toxic for the human cell monolayer.
In conclusion, our results lend experimental support to the use of iron-chelating agents such as lactoferrin, alone or in combination with macrolides, tetracyclines or dihydrofolate reductase inhibitors in P. carinii pneumonia.
